Moleculin Biotech, Inc. (MBRX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | - | - | - | - |
| Research and development | 3,600 | 3,435 | 4,932 | 4,090 |
| General and administrative | 2,091 | 2,477 | 2,172 | 2,064 |
| Depreciation and amortization | 29 | 31 | 31 | 31 |
| Total operating expenses | 5,720 | 5,943 | 7,135 | 6,185 |
| Loss from operations | -5,720 | -5,943 | -7,135 | -6,185 |
| Interest income, net | 26 | 30 | 102 | 159 |
| Gain from change in fair value of warrant liability | -9,609 | -9,054 | 1,728 | -1,696 |
| Transaction costs allocated to warrant liabilities | 1,207 | 1,788 | 993 | - |
| Loss on issuance of warrant liabilities | -10,352 | -7,798 | -847 | - |
| Other income, net | 4 | 9 | 9 | 11 |
| Net loss | -7,640 | -6,436 | -10,592 | -4,319 |
| Foreign currency translation | - | 3 | 14 | 8 |
| Comprehensive loss | -7,640 | -6,433 | -10,578 | -4,311 |
| Net loss per common share - basic and diluted (in dollars per share) | -0.49 | -0.69 | -2.85 | -1.7 |
| Weighted average common shares outstanding, basic and diluted (in shares) | 15,526,401 | 9,343,771 | 3,714,278 | 2,543,244 |